多终点临床试验中多重性问题的统计学方法介绍与应用案例

doi:10.3969/j.issn.1006-7795.2025.02.002

首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (2): 184-190.doi: 10.3969/j.issn.1006-7795.2025.02.002

• 临床研究与方法学应用进展 • 上一篇下一篇

多终点临床试验中多重性问题的统计学方法介绍与应用案例

白秀丹^1,2,3，胥芹^1,2,3，王安心^1,2,3*

1.首都医科大学附属北京天坛医院北京市神经外科研究所流行病学研究室，北京 100070; 2.首都医科大学附属北京天坛医院国家神经系统疾病临床医学研究中心，北京 100070;3.首都医科大学临床流行病学与临床试验学系，北京 100070

收稿日期:2024-11-18 出版日期:2025-04-21 发布日期:2025-04-14
通讯作者: 王安心 E-mail:wanganxin@bjtth.org
基金资助:
北京市自然科学基金项目（L222123）。

Statistical methods and application cases examples for multiplicity issues in multiple endpoints clinical trials

Bai Xiudan^1,2,3，Xu Qin^1,2,3，Wang Anxin^1,2,3*

1.Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;2.China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China;3.Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing 100070, China

Received:2024-11-18 Online:2025-04-21 Published:2025-04-14
Supported by:
This study was supported by Natural Science Foundation of Beijing(L222123).

摘要/Abstract

摘要： 多次检验不调整检验水平而导致总Ⅰ类错误率（familywise error rate，FWER）远远高于预期的情况称为多重性问题。本文首先将基于临床终点的分类和特征介绍多重性问题的产生机制。其次，介绍解决多重性问题的统计检验策略及方法，包括平行策略、序贯策略及其组合策略，不同检验策略的检验结果会有所差异。最后将以国内外研究者发起的临床试验为案例，详述上述常见策略方法的实际应用。临床试验中多终点的多重性调整可通过单一策略或多种策略组合实现。根据所选策略或组合，确定每个检验假设的统计分析方法和显著性水平α，以有效控制多重性问题。

关键词: 临床试验, 多终点, 多重性, 检验策略, 统计学方法

Abstract: Performing multiple tests without adjusting the test level results in a higher-than-intended overall familywise error rate (FWER). This phenomenon is known as the multiplicity problem. In this paper, we first introduced the mechanism of multiplicity problem based on the classification and characterization of clinical endpoints. Then, strategies and methods to solve the multiplicity problem were introduced, including the parallel strategy/single-step method, the sequential strategy/multistep method/stepwise method, and their combinations. The results of different analytic strategies may vary. The practical application of the above common strategies and statistical methods were introduced through the case studies of domestic and foreign investigator initiated clinical trial. Multiplicity adjustment for multiple endpoints in clinical trials can be achieved by a single strategy or a combination of strategies. Depending on the selected strategy or combination, the statistical methods and significance level (denoted as α) for each test hypothesis are determined to effectively control the multiplicity problem.

Key words: clinical trials, multiple endpoints, multiplicity, testing strategies, statistical methods

中图分类号:

白秀丹, 胥芹, 王安心. 多终点临床试验中多重性问题的统计学方法介绍与应用案例[J]. 首都医科大学学报, 2025, 46(2): 184-190.

Bai Xiudan, Xu Qin, Wang Anxin. Statistical methods and application cases examples for multiplicity issues in multiple endpoints clinical trials[J]. Journal of Capital Medical University, 2025, 46(2): 184-190.

参考文献

［1］FDA. Guidance for industry E9 statistical principles for clinical trials［DB/OL］. (1998－09－16)［2024－11－07］. https://www.fda.gov/media/71336/download.
［2］FDA. Multiple endpoints in clinical trials guidance for industry［EB/OL］. (2022－10－21)［2024－11－07］. https://www.fda.gov/media/162416/download.
［3］Pike K T, Reeves B C, Rogers C A. Approaches to multiplicity in publicly funded pragmatic randomised controlled trials: a survey of clinical trials units and a rapid review of published trials［J］. BMC Med Res Methodol, 2022, 22(1): 39.
［4］Khan M S, Khan M S, Ansari Z N, et al. Prevalence of multiplicity and appropriate adjustments among cardiovascular randomized clinical trials published in major medical journals［J］. JAMA Netw Open, 2020, 3(4): e203082.
［5］Andrade C. HARKing, Cherry-picking, P-hacking, fishing expeditions, and data dredging and mining as questionable research practices［J］. J Clin Psychiatry, 2021, 82(1): 33999541.
［6］Chowdhry A K, Park J, Kang J, et al. Finding multiple signals in the noise: handling multiplicity in clinical trials［J］. Int J Radiat Oncol Biol Phys, 2024, 119(3): 750－755.
［7］EMA. Points to consider on multiplicity issues in clinical trials［EB/OL］. (2002－09－19)［2024－11－07］. https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-multiplicity-issues-clinical-trials_en.pdf.
［8］国家食品药品监督管理局. 药物临床试验多重性问题指导原则（试行）［EB/OL］. (2020－12－31) ［2024－11－07］. https://www.cde.org.cn/main/news/viewInfoCommon/a1fd04ab94ffa83aadee4bd1c0327a7f.
［9］Benda N, Brandt A. Regulatory issues with multiplicity in drug approval: principles and controversies in a changing landscape［J］. J Biopharm Stat, 2018, 28(1): 3－9.
［10］Huque M F, Alosh M, Bhore R. Addressing multiplicity issues of a composite endpoint and its components in clinical trials［J］. J Biopharm Stat, 2011, 21(4): 610－634.
［11］Nicholson K J, Sherman M, Divi S N, et al. The role of family-wise error rate in determining statistical significance［J］. Clin Spine Surg, 2022, 35(5): 222－223.
［12］Schulz K F, Grimes D A. Multiplicity in randomised trials I: endpoints and treatments［J］. Lancet, 2005, 365(9470): 1591－1595.
［13］Cui X, Dickhaus T, Ding Y, et al. Handbook of multiple comparisons［M］. New York: Chapman and Hall/CRC, 2021: 36－38.
［14］Dmitrienko A, D'Agostino RB Sr. Multiplicity considerations in clinical trials［J］. N Engl J Med, 2018, 378(22): 2115－2122.
［15］Alosh M, Bretz F, Huque M. Advanced multiplicity adjustment methods in clinical trials［J］. Stat Med, 2014, 33(4): 693－713.
［16］陈峰, 夏结来. 临床试验统计学［M］. 北京: 人民卫生出版社, 2018: 211－223.
［17］Huque M F. Validity of the hochberg procedure revisited for clinical trial applications［J］. Stat Med, 2016, 35(1): 5－20.
［18］Dmitrienko A, Tamhane A C, Wiens B L. General multistage gatekeeping procedures［J］. Biom J, 2008, 50(5): 667－677.
［19］Sedgwick P. Multiple hypothesis testing and Bonferroni's correction［J］. BMJ, 2014, 349: g6284.
［20］Li J J, Mehrotra D V. An efficient method for accommodating potentially underpowered primary endpoints［J］. Stat Med, 2008, 27(26): 5377－5391.
［21］Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance［J］. Biometrika, 1988, 75:800－802.
［22］Yamaguchi Y S E, Sugitani T, Yoshida S, et al. Confirmatory efficacy testing for individual dose-placebo comparisons using serial gatekeeping procedure in dose-finding trials with multiple comparison procedures-modeling［J］. Pharm Stat, 2022, 21(6): 1309－1323.
［23］Ouyang J, Zhang P, Carroll K J, et al. Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures［J］. J Biopharm Stat, 2020, 30(4): 593－606.
［24］李若冰, 曾新, 李新旭, 等. 图示法在多重性问题中的应用及KeyNote-048案例分析［J］. 中国临床药理学杂志, 2022, 38(10): 1146－1150.
［25］Robertson D S, Wason J M S, Bretz F. Graphical approaches for the control of generalized error rates［J］. Stat Med, 2020, 39(23): 3135－3155.
［26］Kelley R K, Rimassa L, Cheng A L, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial［J］. Lancet Oncol, 2022, 23(8): 995－1008.
［27］Zi W J, Song J X, Kong W L, et al. Tirofiban for stroke without large or medium-sized vessel occlusion［J］. N Engl J Med, 2023, 388(22): 2025－2036.
［28］Burtness B, Harrington K J, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study［J］. Lancet, 2019, 394(10212): 1915－1928.

[1]	杨笑, 夏雪, 周全, 郝允逸, 王安心. “希望区域”框架样本量重估在适应性设计临床试验中的应用[J]. 首都医科大学学报, 2025, 46(2): 197-201.
[2]	屈俊达, 杨敏福, 李春林, 孙立伟, 高赫, 张旭. 心外膜脂肪影像分割量化方法及其临床应用的研究进展[J]. 首都医科大学学报, 2025, 46(1): 99-105.
[3]	朱力鸣, 焦昆, 刘伟, 李胜利. 新型同种异体骨修复骨缺损对动物生理生化指标的影响[J]. 首都医科大学学报, 2023, 44(6): 1053-1059.
[4]	嵇江淮, 赵潇潇, 李乾鹏, 安奕, 赵磊, 李冬果. 胶质母细胞瘤中异常甲基化调控的蛋白编码基因识别研究[J]. 首都医科大学学报, 2021, 42(1): 71-76.
[5]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[6]	蒋子雯, 周志敏, 唐红波, 杜博, 张其清, 代荫梅. 乙酰普鲁兰纳米粒子BeWo b30细胞毒性及摄取研究[J]. 首都医科大学学报, 2016, 37(4): 418-423.
[7]	陈新, 罗涛, 黄莹. 新型下腔静脉滤器的研制与应用[J]. 首都医科大学学报, 2016, 37(2): 248-251.
[8]	郭启煜;高妍;丛琳;邵宁生. 瘦素对大鼠肝细胞瘦素受体蛋白、基因表达及酪氨酸磷酸化的影响[J]. 首都医科大学学报, 2007, 28(3): 304-306.
[9]	卢光;张建;李建新;谷涌泉;孙海晨;陈亮;刘庆阳;汪忠镐. 血管组织工程生物材料细胞相容性的评价[J]. 首都医科大学学报, 2006, 27(3): 321-324.
[10]	罗述谦;赵媛媛;阎华;李响. 用活动轮廓法对大脑皮质形态的研究[J]. 首都医科大学学报, 2001, 22(1): 13-16.
[11]	马斌荣. 计算机辅助教学软件的研制和应用的技术要点[J]. 首都医科大学学报, 2000, 21(1): 23-25.
[12]	罗述谦;闫华. 基于可变形表面模型的MR图像脑表面形态提取[J]. 首都医科大学学报, 1999, 20(1): 9-13.
[13]	杜菁;魏民. 中医美容多媒体查询系统的数据库设计[J]. 首都医科大学学报, 1996, 17(2): 107-109.
[14]	马斌荣;魏秉璋. 医学图像三维重构计算机系统及其在医学中的应用[J]. 首都医科大学学报, 1995, 16(2): 109-112.
[15]	燕福生;徐瑞兴;姚志萍. 高效薄层层析法测定罗布麻烟中罗布麻浸膏的含量[J]. 首都医科大学学报, 1992, 13(4): 260-263.

多终点临床试验中多重性问题的统计学方法介绍与应用案例

Statistical methods and application cases examples for multiplicity issues in multiple endpoints clinical trials

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价